Silica-based nanomaterials as drug delivery tools for skin cancer (melanoma) treatment

Skin cancer has emerged as one of the leading types of cancers in the world, causing a high impact on the global burden of health and the economy. Basal cell and squamous cell carcinoma are the localized forms of skin cancer with a high prevalence and can be treated with a high success rate. However, melanoma, a rare type of skin cancer with a high mortality rate, can metastasize and invade other parts of the body. Various skin cancer treatment approaches have been developed and advanced from localized to systemic treatment over the years to improve the low success rate associated with skin cancer, especially metastatic melanoma. The systemic treatment of skin cancer is highly benefitted by drug delivery systems (DDS) designed to function with much higher specificity and lower side effects than the direct treatment with drugs. While many nanomaterials based DDS have been developed in the past few years to take advantage of the small size and high functionality of nanomaterials, silica-based nanomaterials have recently emerged as the flexible DDS with a high biocompatibility, good clearance, a high drug loading capacity, and versatility to attach several drugs and targeting agents to its surface. In this review, recent progress in the treatment of melanoma using silica-based nanomaterials and their hybrids is discussed, highlighting the versatility and potential of these emerging nanomaterials as the DDS for delivering various molecules, including drugs and immunotherapy agents, peptides, and radio- and photo-active agents. The review also introduces various therapies available for the treatment of melanoma, including surgery, chemotherapy, targeted therapy, phototherapy, and immunotherapy and discusses the improvement in these therapies based on silica-based DDS. The review also highlights the role of silica nanomaterials and their hybrids in delivering combination therapy and the advantages of silica nanohybrids over pure silica-based DDS. Finally, we summarize the present status of silica-based nanomaterials in melanoma treatment and the current challenges that have to be solved for the clinical translation of these materials as DDS.

Automated summary

Skin cancer, particularly melanoma, poses a significant global health and economic burden due to its high mortality rate and metastatic potential. Recent advancements in skin cancer treatment, including the use of silica-based nanomaterials as drug delivery systems, show promise in improving treatment outcomes and delivering a variety of therapeutic agents, such as drugs and immunotherapy, to targeted sites. Further research is needed to address the challenges in clinical translation and optimization of silica-based nanomaterials for melanoma treatment.